C.M.D.T.A. Neomed

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Obesity4 trials
• Type 2 diabetes3 trials
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Cushing's syndrome1 trial
• Heart failure1 trial
• Obstructive sleep apnoea1 trial
• Osteoarthritis1 trial
• Peripheral artery disease1 trial
• Prostate cancer1 trial
• Psoriasis1 trial
• Stroke1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Active, not recruiting3 trials
• Completed2 trials
• Not yet recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Eli Lilly and Company5 trials
• Bristol-Myers Squibb1 trial
• Sparrow Pharmaceuticals1 trial

Running trials

• Recruiting

  A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07881458· Phase 3· Eli Lilly and Company· Source

  Contact: Liliana Marin (principal investigator)

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity1 recruiting
• Psoriasis1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

  NCT05929066· Phase 3· Eli Lilly and Company· Source

• Completed

  SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

  NCT05436639· Phase 2· Sparrow Pharmaceuticals· Source